Lorcaserin: a selective serotonin receptor (5-HT2C) agonist for the treatment of obesity
Journal: International Journal of Basic & Clinical Pharmacology (Vol.1, No. 1)Publication Date: 2012-08-01
Authors : Bhaven C. Kataria;
Page : 45-47
Keywords : Anti-obesity drug; Sibutramine; Orlistat; 5-hydroxytryptamine receptor agonist;
Abstract
Lorcaserin is a selective serotonin receptor (5-HT2C) agonist that recently received the U.S. Food and Drug Administration (FDA) approval for chronic weight management. The efficacy of this drug in reducing body weight and improving metabolic parameters of obese patients has been demonstrated in three phase-3 clinical trials. The available evidence indicates that this drug does not show heart valve abnormalities, and the treatment improves the risk factors for type 2 diabetes and cardiovascular diseases. However, the drug's manufacturer will be required to conduct postmarketing studies, including a long-term cardiovascular outcomes trial to assess the effect of Lorcaserin on the risk for major adverse cardiac events such as heart attack and stroke.
Other Latest Articles
- Digoxin toxicity: crucial to diagnose
- A case of refractory multiple myeloma
- Grade 4 oral mucositis and prolonged pancytopenia with high dose intravenous methotrexate in a patient of philadelphia positive acute lymphoblastic leukemia
- A study to evaluate the clinical outcome of drug-eluting vs. bare-metal stents for acute coronary syndrome patients during commercial use in real setting
- Current scenario of rational usage of various drugs in indoor patients
Last modified: 2012-09-02 00:09:53